Save on Opicapone with Coupons, Discounts & Savings Programs

Opicapone is available as 25 mg and 50 mg oral capsules.

Opicapone is a COMT inhibitor and is used to add-on treatment for people with Parkinson’s disease taking carbidopa/levodopa medications (e.g., Sinemet, Rytary) who experience “wearing-off” episodes.

Opicapone is a catechol-O-methyltransferase (COMT) inhibitor. COMT is a protein in your body that breaks down a commonly used Parkinson’s medication called levodopa. This causes levodopa to be less effective at relieving symptoms of Parkinson’s disease, which occur due to low dopamine levels in the brain. By blocking COMT, Opicapone allows levodopa to reach and stay at higher levels in the body. This means more levodopa can be converted into dopamine in the brain to relieve PD symptoms.

The typical dose is 50 mg by mouth once per day at bedtime. For people with moderate liver problems, the typical dose is 25 mg by mouth once per day.

Opicapone is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication in the following:

• Concomitant use of non-selective monoamine oxidase (MAO) inhibitors.
• History of pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms

Common side effects of Opicapone:

• Involuntary movements
• Constipation
• Weight loss

Serious side effects are rare with Opicapone. Contact your healthcare provider immediately if you experience any of the following.

• Excessive sleepiness
• Low blood pressure: dizziness, tiredness, feeling faint
• Symptoms after stopping the medication suddenly: fever, stiff or rigid muscles, confusion

The following medications may interact with Opicapone:

• Non-Selective Monoamine Oxidase (MAO) Inhibitors: Both Opicapone and non-selective MAO inhibitors (e.g., phenelzine, isocarboxazid, and tranylcypromine) inhibit catecholamine metabolism, leading to increased levels of catecholamines. Concomitant use may increase the risk of possible arrhythmias, increased heart rate, and excessive changes in blood pressure
• Concomitant use of Opicapone with non-selective MAO inhibitors is contraindicated. Selective MAO-B inhibitors can be used concomitantly with Opicapone
• Drugs Metabolized by Catechol-O-Methyltransferase (COMT): Concomitant use of Opicapone with drugs metabolized by COMT may affect the pharmacokinetics of those drugs, which may increase the risk of possible arrhythmias, increased heart rate, and excessive changes in blood pressure. Drugs known to be metabolized by COMT should be administered with caution. Monitor for changes in heart rate, rhythm, and blood pressure in patients

• concomitantly treated with Opicapone and drugs metabolized by COMT.

Various FDA-approved generic manufacturers

Based on animal data, Opicapone may cause fetal harm. Tell your healthcare provider if you become pregnant while taking Opicapone.

• Ongentys